27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a report published Monday, LifeTech Capital analyst Stephen M. Dunn downgraded the rating on Echo Therapeutics (NASDAQ: ECTE) from Strong Speculative Buy to Neutral, and removed the $3.75 price target.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
In the report, LifeTech Capital noted, “Echo announced a $12M capital raise at $2.70 ($0.27 pre-split) continuing management's track records of funding missteps resulting in their third consecutive down round in six months ($0.95 Dec., $0.75 Feb., $0.27 June). As can be seen in the graph, despite significant technical and clinical progress for Echo's Symphony® tCGM system, their shares have lost 85% of their value over the past 12 months with a 75% loss in just the past 6 months.”
Echo Therapeutics closed on Friday at $2.78.